The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.